new glp 1 drug retatrutide ππ₯ Retatrutide: The Most Powerful Weight-Loss Yet? π§¬π Phase 3 clinical results are turning heads retatrutide, a next-generation triple-agonist targeting GLP-1, GIP and glucagon receptors, is showing unmatched levels of new glp-1 drug retatrutide Treatment
Description
Its available under brand names Wegovy for weight loss and Ozempic or Rybelsus for type 2 diabetes treatment
The most common risks of oral GLP-1s like Rybelsus, Wegovy pill, and Foundayo include : Acute pancreatitis Diabetic retinopathy complications (diabetes-related vision changes) Hypoglycemia (low blood sugar), especially when used with insulin Kidney or gallbladder issues Severe gastrointestinal reactions Allergic reactions Pulmonary aspiration during general anesthesia or deep sedation All three GLP-1s also carry a black box warning for thyroid tumors based on animal studies
Those numbers look similar but they describe completely different things
The medication he was using required twice-daily injections
Naimi RM, Hvistendahl M, Enevoldsen LH, Madsen JL, Fuglsang S, Poulsen SS, et al
